| |
All
|
ERI quartiles
|
P for trend
|
|---|
|
Q1 (< 2.73)
|
Q2 (2.74–5.36)
|
Q3 (5.37–11.30)
|
Q4 (11.31 ≤)
|
|---|
|
N
|
127
|
32
|
31
|
32
|
32
| |
|
Age (years)
|
67 (59–74)
|
66.5 (51.3–71.0)
|
62.0 (55.0–67.0)
|
71.5 (66.3–80.8)
|
69.5 (63.3–75.8)
|
< 0.001
|
|
Male gender (%)
|
55.1
|
65.6
|
61.3
|
43.8
|
50.0
|
0.271
|
|
Dialysis duration (y)
|
6.7 (2.8–12.3)
|
6.5 (3.7–12.0)
|
9.3 (3.7–13.3)
|
7.0 (3.0–12.8)
|
3.0 (1.8–10.3)
|
0.140
|
|
Smoking (history) (%)
|
44.1
|
43.8
|
54.8
|
37.5
|
40.6
|
0.537
|
|
History of cardiovascular disease (%)
|
19.7
|
15.6
|
12.9
|
31.3
|
18.8
|
0.266
|
|
Body mass index (kg/m2)
|
21.4 (19.0–23.7)
|
23.1 (21.0–25.9)
|
21.2 (19.9–23.1)
|
20.8 (19.1–23.1)
|
20.3 (17.7–22.6)
|
0.006
|
|
Diabetes (%)
|
44.9
|
43.8
|
41.9
|
50.0
|
43.8
|
0.923
|
|
Pre-dialysis SBP (mmHg)
|
150 (136–165)
|
147 (137–158)
|
153 (139–168)
|
154 (133–163)
|
156 (134–173)
|
0.414
|
|
Pre-dialysis DBP (mmHg)
|
80 (71–86)
|
83 (76–88)
|
80 (71–96)
|
74 (66–81)
|
78 (72–88)
|
0.102
|
|
Hemoglobin (g/dL)
|
10.6 (10.1–11.1)
|
11.0 (10.4–11.4)
|
11.0 (10.3–11.3)
|
10.3 (9.8–11.0)
|
10.3 (9.7–10.8)
|
0.002
|
|
Albumin (g/dL)
|
3.5 (3.2–3.7)
|
3.7 (3.4–3.8)
|
3.5 (3.2–3.7)
|
3.4 (3.1–3.7)
|
3.4 (3.1–3.5)
|
0.027
|
|
Calcium (mg/dL)
|
9.2 (8.9–9.6)
|
9.0 (8.7–9.5)
|
9.2 (8.8–9.7)
|
9.5 (9.1–9.7)
|
9.3 (8.9–9.6)
|
0.133
|
|
Phosphorus (mg/dL)
|
5.0 (4.2–5.8)
|
4.8 (4.2–5.6)
|
4.9 (3.8–5.7)
|
5.0 (4.1–5.8)
|
5.3 (4.7–6.0)
|
0.404
|
|
Intact PTH (pg/mL)
|
128 (81–198)
|
151 (95–238)
|
129 (97–169)
|
163 (72–222)
|
100 (65–159)
|
0.125
|
|
C-related protein (mg/dL)
|
0.20 (0.18–0.22)
|
0.20 (0.08–0.20)
|
0.20 (0.08–0.20)
|
0.20 (0.20–0.23)
|
0.20 (0.20–0.29)
|
0.164
|
|
Ferritin (ng/dL)
|
34 (19–71)
|
41 (25–67)
|
24 (18–41)
|
31 (15–83)
|
50 (24–85)
|
0.161
|
|
TSAT (%)
|
24.2 (18.3–29.4)
|
21.4 (15.3–30.4)
|
25.6 (19.5–29.4)
|
26.8 (18.4–30.0)
|
21.7 (17.7–29.6)
|
0.551
|
|
Kt/V
|
1.47 (1.31–1.73)
|
1.45 (1.25–1.72)
|
1.64 (1.27–1.74)
|
1.51 (1.42–1.80)
|
1.40 (1.31–1.72)
|
0.345
|
|
ESA type (%)
|
|
Darbepoetin alfa
|
91.3
|
100
|
100
|
96.8
|
68.8
|
< 0.001
|
|
Epoetin beta pegol
|
8.7
|
0
|
0
|
3.2
|
31.3
|
< 0.001
|
|
ESA dose (μg/week)
|
|
Darbepoetin alfa
|
15 (10–20)
|
5 (5–5)
|
10 (10–15)
|
20 (15–20)
|
40 (38–60)
|
< 0.001
|
|
Epoetin beta pegol
|
75 (50–100)
|
NA
|
NA
|
25 (25–25)
|
75 (75–100)
|
< 0.001
|
|
ERI
|
5.36 (2.73–11.31)
|
1.61 (1.36–2.21)
|
4.32 (3.45–4.81)
|
7.37 (6.11–9.43)
|
20.42 (14.76–24.45)
|
< 0.001
|
|
ARB or ACEi (%)
|
62.2
|
59.4
|
64.5
|
62.5
|
62.5
|
0.980
|
- Data are expressed as median (interquartile range). P values were obtained by comparison across all four groups using the Kruskal-Wallis test and χ2 test, as appropriate. ERI erythropoietin resistance index, SBP systolic blood pressure, DBP diastolic blood pressure, PTH parathyroid hormone, TSAT transferrin saturation, ESA erythropoietin-stimulating agent, ARB angiotensin receptor blocker, ACEi angiotensin-converting enzyme inhibitor
